Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05127174 · ClinicalTrials.gov registry record · Phase 1
Maintenance Fedratinib to Prevent Post-Transplant Relapse in Myeloproliferative Neoplasms
A Phase 1 study, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- Terminated
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT05127174 is a Phase 1 study that was terminated before completion, run by H. Lee Moffitt Cancer Center and Research Institute. The registered enrollment target is 12 participants.
The verdict
NCT05127174, a Phase 1 study, was terminated before completion, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
The purpose of the study is to evaluate the effectiveness and safety of fedratinib as maintenance therapy in participants with myeloproliferative neoplasms (MPNs) after allogeneic hematopoietic cell transplant (HCT).
Interventions
- DRUG Fedratinib Pill
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2022-03-14 |
| Est. Completion | 2025-01-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05127174
The ClinicalTrials.gov registry entry for NCT05127174 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is H. Lee Moffitt Cancer Center and Research Institute, which has 502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Fedratinib Pill is the first listed.
NCT05127174 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05127174 about?
NCT05127174 is a clinical study titled "Maintenance Fedratinib to Prevent Post-Transplant Relapse in Myeloproliferative Neoplasms". The purpose of the study is to evaluate the effectiveness and safety of fedratinib as maintenance therapy in participants with myeloproliferative neoplasms (MPNs) after allogeneic hematopoietic cell transplant (HCT).
What is the current status of trial NCT05127174?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2022-03-14. Estimated completion is 2025-01-03.
What interventions are being tested in trial NCT05127174?
The interventions under investigation include: Fedratinib Pill (DRUG).
Who is sponsoring clinical trial NCT05127174?
This trial is sponsored by H. Lee Moffitt Cancer Center and Research Institute, which has 502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.